[1] 中华医学会核医学分会.  131I治疗格雷夫斯甲亢指南(2013版)[J]. 标记免疫分析与临床, 2014, 21(1): 92-104.   doi: 10.11748/bjmy.issn.1006-1703.2014.01.030
Chinese Society of Nuclear Medicine.  Clinical guidelines for 131I treatment of Graves' hyperthyroidism (2013 edition)[J]. Labeled Immunoassays & Clin Med, 2014, 21(1): 92-104.   doi: 10.11748/bjmy.issn.1006-1703.2014.01.030
[2] Gianoukakis AG, Leigh MJ, Richards P, et al.  Characterization of the anaemia associated with Graves' disease[J]. Clin Endocrinol (Oxf), 2009, 70(5): 781-787.   doi: 10.1111/j.1365-2265.2008.03382.x
[3] 刘真真, 李冲, 李婕一, 等.  Graves病合并血液系统异常537例临床分析[J]. 郑州大学学报: 医学版, 2014, 49(2): 291-293.   doi: 10.13705/j.issn.1671-6825.2014.02.042
Liu ZZ, Li C, Li JY, et al.  Clinical analysis of 537 cases of Graves disease complicated with hematological abnormalities[J]. J Zhengzhou Univ (Med Sci), 2014, 49(2): 291-293.   doi: 10.13705/j.issn.1671-6825.2014.02.042
[4] Sehgal S, Tamatea JAU, Conaglen JV, et al.  Anaemia and thyrotoxicosis: the need to look for an alternative cause[J]. Clin Endocrinol (Oxf), 2018, 88(6): 957-962.   doi: 10.1111/cen.13598
[5] Cao J, Li HY, Yuan RB, et al.  Protective effects of new aryl sulfone derivatives against radiation-induced hematopoietic injury[J]. J Radiat Res, 2020, 61(3): 388-398.   doi: 10.1093/jrr/rraa009
[6] 周美娟, 郑莉, 丁振华.  辐射对造血系统的影响[J]. 国外医学放射医学核医学分册, 2004, 28(3): 139-142.   doi: 10.3760/cma.j.issn.1673-4114.2004.03.011
Zhou MJ, Zheng L, Ding ZH.  Hematopoietic system responses of ionization radiation exposure[J]. Foreign Med Sci Sec Radiat Med Nucl Med, 2004, 28(3): 139-142.   doi: 10.3760/cma.j.issn.1673-4114.2004.03.011
[7]

张永学, 黄钢. 核医学[M]. 2版. 北京: 人民卫生出版社, 2010: 422.

Zhang YX, Huang G. Nuclear medicine[M]. 2nd ed. Beijing: People's Health Publishing House, 2010: 422.
[8] Inoue T, Hirabayashi Y, Mitsui H, et al.  Survival of spleen colony-forming units (CFU-S) of irradiated bone marrow cells in mice: evidence for the existence of a radioresistant subfraction[J]. Exp Hematol, 1995, 23(12): 1296-1300.
[9] Canto AU, Dominguez PN, Jimeno CA, et al.  Comparison of fixed versus calculated activity of radioiodine for the treatment of graves disease in adults[J]. Endocrinol Metab (Seoul), 2016, 31(1): 168-173.   doi: 10.3803/EnM.2016.31.1.168
[10] 徐智军, 于鹏, 梁英魁, 等.  放射性核素131I在甲亢治疗中的安全性与有效性[J]. 现代生物医学进展, 2017, 17(19): 3762-3764.   doi: 10.13241/j.cnki.pmb.2017.19.041
Xu ZJ, Yu P, Liang YK, et al.  Efficacy and safety of radionuclide 131I in the treatment of hyperthyroidism[J]. Prog Mod Biomed, 2017, 17(19): 3762-3764.   doi: 10.13241/j.cnki.pmb.2017.19.041
[11] 王任飞, 谭建, 张桂芝, 等.  2125例甲状腺功能亢进患者131I治疗的回顾性分析[J]. 中华内分泌代谢杂志, 2015, 31(5): 421-426.   doi: 10.3760/cma.j.issn.1000-6699.2015.05.010
Wang RF, Tan J, Zhang GZ, et al.  Analysis of 2125 patients with hyperthyroidism after 131I therapy: a retrospective study[J]. Chin J Endocrinol Metab, 2015, 31(5): 421-426.   doi: 10.3760/cma.j.issn.1000-6699.2015.05.010
[12] 李建芳, 秦露平, 谢良骏, 等.  单次131I治疗甲亢5年随访疗效分析[J]. 新医学, 2018, 49(9): 656-659.   doi: 10.3969/j.issn.0253-9802.2018.09.009
Li JF, Qin LP, Xie LJ, et al.  Five-year follow-up of clinical efficacy of single 131I therapy in hyperthyroidism patients[J]. New Med, 2018, 49(9): 656-659.   doi: 10.3969/j.issn.0253-9802.2018.09.009
[13] 董佳佳, 章斌, 韩江琴, 等.  131I治疗合并肝损害Graves甲亢的疗效分析[J]. 标记免疫分析与临床, 2020, 27(12): 2063-2066.   doi: 10.11748/bjmy.issn.1006-1703.2020.12.010
Dong JJ, Zhang B, Han JQ, et al.  The efficacy of 131I treatment in patients of Graves' disease combined with hepatic function injury[J]. Labeled Immunoassays & Clin Med, 2020, 27(12): 2063-2066.   doi: 10.11748/bjmy.issn.1006-1703.2020.12.010
[14] 田琦, 蒋宁一, 郑丽.  265例精细个体化131I治疗Graves甲亢的疗效观察[J]. 国际放射医学核医学杂志, 2016, 40(4): 259-262.   doi: 10.3760/cma.j.issn.1673-4114.2016.04.004
Tian Q, Jiang NY, Zheng L.  Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J]. Int J Radiat Med Nucl Med, 2016, 40(4): 259-262.   doi: 10.3760/cma.j.issn.1673-4114.2016.04.004